The LTC Innovation Blog

The sale of Omnicare's LTC pharmacy business is not just another healthcare transaction. It is a clear signal that the the economic and operational realities facing long-term care (LTC) pharmacy are shifting in ways that affect every type of provider in the market, big or small. On May 13, 2026, the U.S. Bankruptcy Court for the Northern District of Texas approved the $250 million sale of Omnicare — a subsidiary of CVS Health - to GenieRx Holdings LLC, a joint partnership between private investment firm Milrose Capital LLC and healthcare investment and management firm Integro Asset Management LLC, operating as Integro Healthcare Services. The transaction is expected to close later in 2026, pending regulatory approval, with Omnicare continuing to serve its clients through the transition period. Omnicare filed for Chapter 11 bankruptcy in September 2025, citing a combination of legal proceedings and broader financial pressures facing the long-term care pharmacy sector. Those pressures had been building for some time. Omnicare is not the only enterprise in the broader LTC sector to face significant financial strain. Genesis Healthcare, one of the nation's largest skilled nursing facility operators, filed Chapter 11 bankruptcy in July 2025 with $2.3 billion in debt, a signal that the financial pressure is not confined to any single organization but is being felt across the sector. For LTC pharmacies, the important question is not what happened to Omnicare specifically. It is what this moment says about the environment every provider is operating in today.